Laboratory Investigation

Kidney International (1991) 40, 418–424; doi:10.1038/ki.1991.228

Binding inhibitors restore furosemide potency in tubule fluid containing albumin

Kent A Kirchner, James R Voelker and Craig D Brater

Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi and Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana

Correspondence: Kent A Kirchner MD, University of Mississippi Medical Center, Department of Medicine, 2500 North State Street, Jackson, Mississippi 39216-4505, USA.

Received 15 October 1990; Revised 30 April 1991; Accepted 1 May 1991.

Top

Abstract

Binding inhibitors restore furosemide potency in tubule fluid containing albumin. We have previously suggested that albumin in tubule fluid at concentrations found in the nephrotic syndrome (NS) binds furosemide, thereby diminishing diuretic effect. This mechanism may contribute to diuretic resistance in NS. If this hypothesis is correct, displacement of albumin from furosemide should restore diuretic response in tubule fluid containing albumin. To test this supposition, in vivo loop microperfusion was performed in rats using perfusates containing 6 microM furosemide in the presence or absence of 3.8 microM albumin, or furosemide and albumin to which 12 microM warfarin or 5.4 mM sulfisoxazole had been added. These drugs are inhibitors of albumin-furosemide binding in plasma. Albumin in the perfusate impaired furosemide effect on loop chloride reabsorption (1248 plusminus 59 vs. 886 plusminus 65 pEq/min; P < 0.05). Addition of warfarin or sulfisoxazole to perfusate containing albumin normalized furosemide's effect. Neither drug affected furosemide response in the absence of albumin. Dansylsarcosine, a probe that binds albumin at a different site than furosemide, failed to normalize furosemide response in albumin perfusates. These data suggest that albumin in tubule fluid reduces diuretic response through a diminution in the free furosemide concentration. In as much as this mechanism contributes to diuretic resistance observed clinically in NS, displacement of furosemide from albumin binding sites may be a therapeutic strategy warranting study.

Top

References

  1. Keller E, Hoppe-Seyler G, Schollmeyer P: Disposition and diuretic effect of furosemide in nephrotic syndrome. Clin Pharmacol Ther 32:442–449, 1982
  2. Smith DE, Hyneck ML, Berardi RR, Port FK: Urinary protein binding, kinetics and dynamics of furosemide in nephrotic patients. J Pharm Sci 74:603–607, 1985
  3. Kirchner KA, Voelker JR, Brater DC: Intratubular albumin blunts the response to furosemide-A mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 252:1097–1101, 1990 | PubMed | ChemPort |
  4. Sjoholm I, Ekman B, Kober A, Ljungstedt-Pahlman I, Seiving B, Sjodin T: Binding of drugs to human serum albumin XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol 16:767–777, 1979
  5. Kirchner KA: Prostaglandin inhibitors alter loop segment chloride uptake during furosemide diuresis. Am J Physiol 248 (Renal Fluid Electrol Physiol 17):F698–F704, 1985
  6. Schlatter E, Greger R, Weidtke C: Effect of "high ceiling" diuretics on active salt transport in the cortical thick ascending limb of Henle's loop of rabbit kidney. Pflügers Arch 396:210–217, 1983 | Article | ChemPort |
  7. Lewy JE, Pesce A: Micropuncture study of albumin transfer in aminonucleoside nephrosis in the rat. Pediatr Res 7:553–559, 1973 | PubMed | ISI | ChemPort |
  8. Nelson E, O'Reilly I: Kinetics of sulfisoxazole acetylation and excretion in humans. J Pharmacol Exp Ther 129:368–372, 1960
  9. Benet LZ, Sheiner LB: Pharmacokinetics: The dynamics of drug absorption, distribution and elimination, in Goodman and Gilman's, The Pharmacological Basis of Therapeutics (7th ed), edited by AG Gilman LS, Goodman TW, Rall F, Murad New York, McMillan Publishing Co., pp. 3–34
  10. Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, Nagase S, Morino Y: Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 32:198–203, 1987 | PubMed | ChemPort |
  11. Ikeda K, Morizono T: Effect of albumin-bound furosemide on endocochlear potential of the chinchilla. Arch Otolaryngol Head Neck Surg 115:500–502, 1989
  12. Green TP, Mirkin BL: Resistance of proteinuric rats to furosemide: Urinary drug protein binding as a determinant of drug effect. Life Sci 26:623–630, 1980
  13. Ichikawa I, Rennke H, Hoyer JR, Badr KF, Schor N, Troy JL, Lechene CP, BrenneR BM: Role of intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Investi 1:91–103, 1983
  14. Voelker JR, Jameson DM, Brater DC: In vitro evidence that urine composition affects the fraction of active furosemide in nephrotic syndrome. J Pharmacol Exp Ther 250:772–778, 1989 | PubMed | ChemPort |
  15. Gutsche H-U, Muller-Ott K, Brunkhorst R, Niedermayer W: Dose-related effects of furosemide, butmetanide and piretanide on the thick ascending limb function in the rat. Can J Physiol Pharmacol 61:159–165, 1983
  16. Brodie BB: Displacement of one drug by another from carrier or receptor sites. Proc Roy Soc Med 58:946–955, 1965
  17. ButtneR H, Portwich F: Kompetitionsphanomene bei der binding von pharmaka an albumin. Klin Wochschr 45:225–230, 1967
  18. Silverman WA, Anderson DH, Blane WA, Crozier DN: A difference in mortality rate and incidence of kernicterus among premature infants alloted to two prophylactic antibacterial regimens. Pediatrics 18:614–625, 1956 | PubMed | ISI |

Extra navigation

.
ADVERTISEMENT